Physician profile
Daniel P Sanchez
NPI 1912994781
$3,229.60
in general payments reported to CMS, 2019-2025
16 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $251 · 2021: $312 · 2022: $282 · 2023: $232 · 2024: $1,013 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,378.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $415.56 | 2023-2024 | |
| Amgen INC. | $257.80 | 2024 | Evenity |
| Novo Nordisk INC | $256.38 | 2019-2022 | |
| Abbvie INC. | $171.20 | 2022-2024 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $142.74 | 2019-2024 | Trelegy Ellipta |
| Pfizer INC. | $124.97 | 2025 | |
| United Therapeutics Corporation | $115.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $94.80 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.74 | 2019 | |
| Lilly USA, LLC | $54.36 | 2022-2025 | Zepbound, Mounjaro, Emgality |
| Shield Therapeutics INC | $42.63 | 2025 | |
| Abbott Laboratories | $39.56 | 2020 | |
| Dexcom, INC. | $23.04 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $20.31 | 2025 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $17.35 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.